Dentsply Sirona (XRAY)
(Delayed Data from NSDQ)
$26.90 USD
+0.19 (0.71%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $26.91 +0.01 (0.04%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.90 USD
+0.19 (0.71%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $26.91 +0.01 (0.04%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth B Momentum A VGM
Zacks News
QIAGEN (QGEN) to Win U. N. Accolade for QuantiFERON-TB Access
by Zacks Equity Research
This acclaim marks a giant leap for QIAGEN (QGEN) in the field of tuberculosis diagnosis.
AngioDynamics IDE Application for NanoKnife Gets FDA Nod
by Zacks Equity Research
AngioDynamics' (ANGO) pilot study is intended to support the approval of a future PMA in the United States.
Hologic Breast Health Arm Aids Strongly, Rising Costs Ail
by Zacks Equity Research
Within Breast Health, Hologic (HOLX) unveils a string of products including 3Dimensions and 3D Performance gantries, Clarity HD, SmartCurve, Affirm prone biopsy system and Brevera biopsy system.
Will RTG Again Bolster Medtronic's (MDT) Earnings in Q4?
by Zacks Equity Research
Within Neurovascular, we hope to witness strength across Medtronic's (MDT) stroke franchise with growth in stent retrievers, flow diverters, neuro access and embolic products.
ResMed Study Shows Remote Monitoring Benefits on CPAP Use
by Zacks Equity Research
Results of this study mark a remarkable feat for ResMed's (RMD) medical innovation aimed at treating people suffering from sleep apnea.
Here's Why You Should Buy Masimo (MASI) Stock Right Now
by Zacks Equity Research
Masimo (MASI) benefits from launches like Halo ION.
Avedro (AVDR) Hits a 52-Week High on Solid Growth Prospects
by Zacks Equity Research
Avedro (AVDR) gains from promising developments in recent times.
Varian Medical's CTSI Buyout to Boost Oncology Services Unit
by Zacks Equity Research
The CTSI buyout is expected to prove accretive to Varian Medical's (VAR) adjusted earnings per share during fiscal 2021.
Why Should You Hold on to Myriad Genetics (MYGN) Stock?
by Zacks Equity Research
Investor confidence is still high on growth prospects of Myriad Genetics (MYGN).
LabCorp Grows on Strong Diagnostics Arm Amid Contract Losses
by Zacks Equity Research
LabCorp's (LH) diagnostics business grows organically despite additional price reductions.
Medtronic (MDT) Launches Telescope Guide Extension Catheter
by Zacks Equity Research
The launch of Telescope marks Medtronic's (MDT) foray into the guide extension catheter market.
ABIOMED (ABMD) to Launch Impella CP With SmartAssist at SCAI
by Zacks Equity Research
ABIOMED's (ABMD) Impella CP receives Japanese PMDA approval in recent times.
Here's Why You Should Hold on to Tandem (TNDM) Stock for Now
by Zacks Equity Research
Investor confidence in Tandem Diabetes (TNDM) is still high on several positive factors.
Varian Medical Installs ProBeam at Research Hub in Singapore
by Zacks Equity Research
Varian Medical's (VAR) APAC revenues grow 7% year over year in the fiscal second quarter.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
ResMed (RMD) continues to see strong sales from SaaS business as well as new mask products and devices.
Integra LifeSciences Rides on Product Launch, Faces Rivalry
by Zacks Equity Research
Benefiting from new products and an improved sales force performance, Integra LifeSciences (IART) projects speedy organic growth in the second half of 2019.
STERIS (STE) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
STERIS (STE) witnesses solid revenue growth across each of its operating segments in the reported quarter.
Medtronic to Acquire Titan Spine for Spine Portfolio Boost
by Zacks Equity Research
According to Medtronic (MDT), interbody implants material and shape play a vital role in the bone growth process during fusions and presently, titanium interbody devices are rapidly becoming popular.
ABIOMED's Impella 5.0 and LD Receive Expanded FDA Approvals
by Zacks Equity Research
ABIOMED's (ABMD) FDA-approved Impella 2.5 and Impella CP treat certain advanced heart failure patients.
Abbott Rides on Strong CGM, Poor Rhythm Management Ails
by Zacks Equity Research
Abbott (ABT) is attracting constant attention with developments in its flagship, sensor-based continuous glucose monitoring (CGM) system called FreeStyle Libre System.
Medtronic's (MDT) EV ICD Pilot Study Results Encourage
by Zacks Equity Research
The study highlights the benefits of traditional, transvenous ICDs offered by the Medtronic's (MDT) EV ICD system.
Nevro (NVRO) Q1 Loss Wider Than Expected, Revenues Down Y/Y
by Zacks Equity Research
Nevro's (NVRO) domestic and international revenues fall year over year in Q1.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) has been gaining investor confidence on robust performance.
National Vision's (EYE) Q1 Earnings Beat, Margins Decline
by Zacks Equity Research
National Vision's (EYE) consistent strength in comps is owing to higher customer transaction for the past 69 straight quarters.
Syneos' (SYNH) Q1 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
Syneos Health (SYNH) sees strong year-over-year revenue growth across both operating segments ??? Clinical Solutions and Commercial Solutions.